| 01/21/2021 15:00 |
Start of a Japanese Clinical Study of TAK-919, Moderna's COVID-19 Vaccine Candidate |
| 12/17/2020 00:30 |
2020 Sustainability Report |
| 12/08/2020 18:00 |
Wave 1 Pipeline Market Opportunity Conference Call (on December 9, 2020) Presentation |
| 11/30/2020 17:00 |
The 144th (interim period) Business Report |
| 11/24/2020 16:00 |
Announcementof Making Nihon Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary Through Simple Share Exchange |
| 10/29/2020 15:00 |
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan |
| 10/29/2020 15:00 |
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) |
| 10/29/2020 15:00 |
Summary of Financial Statements for the Six-month Period Ended September 30, 2020 (IFRS,Consolidated) |
| 10/09/2020 08:30 |
First Patient Enrolled in Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine |
| 09/24/2020 17:30 |
Announcement of decision on a basic plan for a merger (simple merger/short-form merger) with a wholly-owned subsidiary |
| 08/24/2020 16:00 |
Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion |
| 08/07/2020 18:00 |
Novavax and Takeda Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan |
| 08/03/2020 15:00 |
Announcement of a merger (simple merger/short-form merger) with a wholly-owned subsidiary |
| 07/31/2020 15:00 |
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) |
| 07/31/2020 15:00 |
Summary of Financial Statements for the Three-month Period Ended June 30, 2020 (IFRS,Consolidated) |
| 07/29/2020 15:45 |
Corporate Governance Report 2020/07/29 |
| 06/30/2020 08:30 |
Takeda Announces Pricing of its Unsecured U.S. Dollar-Denominated Senior Notes and Unsecured Euro-Denominated Senior Notes |
| 06/29/2020 12:00 |
Takeda Announces Anticipated Financial Impact from Novartis' withdrawal of the Marketing Authorisation Application for Xiidra |
| 06/25/2020 17:30 |
Takeda Announces Proposed Issuance of Unsecured U.S. Dollar-Denominated Senior Notes and Unsecured Euro-Denominated Senior Notes |
| 06/24/2020 16:30 |
Notice Concerning Filing of Shelf Registration Statement in Japan |
| 06/24/2020 16:30 |
Launch of a New Employee Stock Purchase Plan and Long-Term Incentive Plan for Company Group Employees Overseas |
| 06/22/2020 17:30 |
Update of the Financial Impact of the European Commission's Decision to Release Takeda from Commitment to Divest Shire's Pipeline Compound SHP647 |
| 06/19/2020 08:00 |
Partial Correction to the Items Disclosed via the Internet Concerning the Notice of Convocation of the 144th Ordinary General Meeting of Shareholder |
| 05/29/2020 08:00 |
European Commission Releases Takeda from Commitment to Divest Shire's Pipeline Compound SHP647 |
| 05/28/2020 08:00 |
Takeda's Executive Compensation Overview |
| 05/28/2020 08:00 |
Message from Christophe Weber, President & CEO |
| 05/28/2020 08:00 |
Items Disclosed via the Internet Concerning the Notice of Convocation |
| 05/28/2020 08:00 |
Notice of Convocation of the 144th Ordinary General Meeting of Shareholders |
| 05/15/2020 18:30 |
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Group Management in Fiscal Year 2020 |
| 05/15/2020 18:30 |
Notice of the Opinion of the Board of Directors regarding a Shareholder Proposal |
| 05/15/2020 18:30 |
Takeda Announces Candidates for New Directors |
| 05/13/2020 15:00 |
Difference between Forecast and Actual Results for the Year Ended March 2020 |
| 05/13/2020 15:00 |
Financial Statements for the Fiscal Year Ended March 31, 2020 (IFRS, Consolidated) |
| 04/06/2020 19:45 |
GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY |
| 04/04/2020 00:30 |
2019 SUSTAINABLE VALUE REPORT (2/2) |
| 04/04/2020 00:30 |
2019 SUSTAINABLE VALUE REPORT (1/2) |
| 04/01/2020 10:00 |
Takeda Adopts Executive Compensation Recoupment Policy |
| 03/04/2020 17:00 |
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19 |
| 02/04/2020 15:00 |
Notice of the Revised Forecast of Cosolidated Financials for FY2019 (IFRS) |
| 02/04/2020 15:00 |
Financial Statements for the Nine-month Period Ended December 31, 2019 (IFRS, Consolidated) |
